Idarubicin-loaded microspheres for treating liver cancer
Author Information
Author(s): Spela Korsic, Josko Osredkar, Alojz Smid, Klemen Steblovnik, Mark Popovic, Igor Locatelli, Jurij Trontelj, Peter Popovic
Primary Institution: Clinical Institute of Radiology, University Medical Centre Ljubljana
Hypothesis
This study aimed to evaluate safety, efficacy, and pharmacokinetics of idarubicin-loaded drug-eluting microspheres TACE (DEMIDA-TACE) in intermediate stage HCC patients.
Conclusion
DEMIDA-TACE is a safe and effective treatment for intermediate stage HCC, showing high tumor response and favorable overall survival.
Supporting Evidence
- Adverse events grade ≥ 3 were noted after 29.4% of procedures.
- The overall objective response rate was 83.9%.
- Median progression-free survival was 10.5 months.
- Median overall survival was 36.0 months.
- Idarubicinol plasma concentrations at 72 hours may predict treatment response.
Takeaway
Doctors used a special type of medicine to treat liver cancer, and it worked really well with few side effects.
Methodology
The study involved 31 patients treated with idarubicin-loaded microspheres, evaluating safety, efficacy, and pharmacokinetics over multiple procedures.
Limitations
The study was conducted at a single institution with a small sample size and lacked a control group.
Participant Demographics
Most participants were male (90.3%) with a mean age of 70.6 years, and 96.8% had cirrhosis.
Statistical Information
P-Value
0.014
Confidence Interval
95% CI: 6.8–14.3 months for PFS; 95% CI: 21.1–50.9 months for OS
Statistical Significance
p = 0.014
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website